Study of BMS-275183 in Patients With Pretreated Locally Advanced or Metastatic NSCLC (Non Small Cell Lung Cancer)
NCT ID: NCT00359450
Last Updated: 2010-03-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE2
186 participants
INTERVENTIONAL
2006-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* Cohort I: Patients previously treated with one taxane containing regimen.
* Cohort II: Patients previously treated with a platinum based but non-taxane containing regimen.
* Cohort III: Patients previously treated with both a chemotherapy regimen and one EGFR-TKI (epidermal growth factor receptor-tyrosine kinase inhibitor) compound.
Patients in cohorts I and II should have not been treated with a prior EGFR-TKI compound. Prior treatment with a VEGFR (vascular endothelial growth factor receptor) inhibitor compound is allowed for all the patients provided that the VEGFR inhibitor is not also an EGFR inhibitor.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of BMS-275183 in Patients With Pre-treated Non-small Cell Lung Cancer
NCT00099879
Safety and Efficacy of Buparlisib (BKM120) in Patients With Untreated Squamous Non-small Cell Lung Cancer
NCT01820325
Oral Taxane in Combination With Pemetrexed (Alimta) in Patients With Recurrent Non-Small Cell Lung Cancer
NCT00103831
Phase II Study of Buparlisib + Docetaxel in Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) Patients
NCT01911325
Safety and Efficacy of BKM120 in Patients With Metastatic Non-small Cell Lung Cancer
NCT01297491
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
BMS-275183 (oral taxane)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subjects with histologically or cytologically confirmed locally advanced or metastatic NSCLC who failed only one prior chemotherapy regimen.
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bristol-Myers Squibb
INDUSTRY
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Local Institution
Burlington, Massachusetts, United States
Local Institution
St Louis, Missouri, United States
Local Institution
Morganton, North Carolina, United States
Local Institution
Cleveland, Ohio, United States
Local Institution
Charleroi, , Belgium
Local Institution
Leuven, , Belgium
Local Institution
Montreal, Ontario, Canada
Local Institution
Thunder Bay, Ontario, Canada
Local Institution
Toronto, Ontario, Canada
Local Institution
Saint-Jérôme, Quebec, Canada
Local Institution
Belfort, , France
Local Institution
Besançon, , France
Local Institution
Poitiers, , France
Local Institution
Saint-Herblain, , France
Local Institution
Strasbourg, , France
Local Institution
Tours, , France
Local Institution
Napoli, , Italy
Local Institution
Orbassano Torino, , Italy
Local Institution
Perugia, , Italy
Local Institution
Roma, , Italy
Local Institution
Amsterdam, , Netherlands
Local Institution
Maastricht, , Netherlands
Local Institution
Barcelona, , Spain
Local Institution
Madrid, , Spain
Local Institution
Cambridge, Cambridgeshire, United Kingdom
Local Institution
Glasgow, Central, United Kingdom
Local Institution
Plymouth, Devon, United Kingdom
Local Institution
London, Greater London, United Kingdom
Local Institution
Northwood, Middlesex, United Kingdom
Local Institution
Oxford, Oxfordshire, United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EUDRACT: 2005-005099-33
Identifier Type: -
Identifier Source: secondary_id
CA165-026
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.